Testing 2-HOBA to Improve Good Cholesterol in Familial Hypercholesterolemia
Tests 2-HOBA against placebo in adults with inherited high cholesterol.
Plain-language title generated from the registry record
Registry title: 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Key facts
- Where
- Nashville, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 69 years old?
Source: NCT04941599, who can take part
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vanderbilt University Medical Center
- Trial code
- NCT04941599
- Record updated
- 7 August 2026
- Original description
The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.Read full original descriptionShow less
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.
Inclusion: Individuals with heterozygous Familial Hypercholesterolemia.
Exclusion: evidence of a previous acute coronary syndrome,; Myocardial infarction or stroke within the last 6 months; unstable angina, symptoms of angina within the last 3 months; poorly controlled hypertension: SBP > 180 mm Hg or DBP > 110 mm Hg,; individuals with Type 2 Diabetes Mellitus, obesity (BMI > 30),; renal insufficiency (Cr > 1.8),; nephrotic syndrome,; AIDS or HIV; history of malignancy of any organ in last 5 years; NYHA class III or IV heart failure or LVEF < 30%; hypertriglyceridemia (fasting TG > 250 mg/dl),; hepatic disease (aspartate aminotransferase(AST) or alanine aminotransferase (ALT) > 2x ULN),; pregnancy,; current smokers,; hypothyroidism,; rheumatoid arthritis,; systemic lupus erythematosus,.